gms | German Medical Science

20. Jahrestagung der Deutschen Gesellschaft für Thoraxchirurgie

Deutsche Gesellschaft für Thoraxchirurgie

22.09. bis 24.09.2011, Düsseldorf-Kaiserswerth

Analysis of clinically theranostic relevant genes, EGFR and KRAS, in subtypes of non-small cell lung cancer (NSCLC) patients

Meeting Abstract

  • Melanie Demes - HSK (Dr. Horst Schmidt Kliniken), IPZ (Institut für Pathologie und Zytologie), Wiesbaden
  • Stefanie Scheil-Bertram - HSK (Dr. Horst Schmidt Kliniken), IPZ (Institut für Pathologie und Zytologie), Wiesbaden
  • Holger Bartsch - HSK (Dr. Horst Schmidt Kliniken), IPZ (Institut für Pathologie und Zytologie), Wiesbaden
  • Joachim Schirren - HSK (Dr. Horst Schmidt Kliniken), Thoraxchirugie, Wiesbaden
  • Servet Bölükbas - HSK (Dr. Horst Schmidt Kliniken), Thoraxchirugie, Wiesbaden
  • Norbert Frickhofen - HSK (Dr. Horst Schmidt Kliniken), Onkologie, Hämatologie, Palliativmedizin, Wiesbaden
  • Annette Fisseler-Eckhoff - HSK (Dr. Horst Schmidt Kliniken), IPZ (Institut für Pathologie und Zytologie), Wiesbaden

Deutsche Gesellschaft für Thoraxchirurgie. 20. Jahrestagung der Deutschen Gesellschaft für Thoraxchirurgie. Düsseldorf, 22.-24.09.2011. Düsseldorf: German Medical Science GMS Publishing House; 2011. DocFV 1.7

DOI: 10.3205/11dgt46, URN: urn:nbn:de:0183-11dgt467

Published: September 19, 2011

© 2011 Demes et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.


Outline

Text

Aims: Genetic alterations in KRAS and EGFR oncogenes are poorly investigated in squamous cell carcinoma (SCC). In a single study, we evaluated the frequency of these cancer relevant genes in adenocarcinoma (ADC) and SSC to gain further inside into the significance of EGFR in NSCLCs and to explore whether these mutations are restricted to an adenocarcinoma component.

Methods: Tumor samples of 741 patients suffering from stage III to IV NSCLC were investigated. KRAS mutations were investigated by Sequencing and SNaPshot. The molecular status of EGFR exon 19 and exon 21 were analyzed by fragment analysis. Mutations in EGFR exon 18 were assayed by direct sequencing and mutation-specific polymerase chain reaction.

Results: The 733 NSCLC samples comprised 147 (20.1%) pure squamous cell carcinoma and 586 (79.9%) pure adenocarcinoma. No coexisting mutations of EGFR and KRAS occurred in adenocarcinoma and squamous cell carcinoma, respectively. EGFR mutations were detected in 7 of 140 (5%) squamous cell carcinoma (5% in exon 21) and in 108 of 586 (18.4%) adenocarcinoma (8.5% in exon 19, 10.2% in exon 21 and <1% in exon 18).

7 of 95 (7.4%) squamous cell carcinoma and 79 of 243 (32.5%) adenocarcinoma were characterized as KRAS-mutation positive ones.

Conclusion: In conclusion somatic mutations of EGFR and KRAS genes develop in squamous cell carcinoma. Patients with such genetic alterations are thus potential candidates for chemotherapeutic treatments targeting EGFR. Therefore EGFR mutational analysis should be performed not only in adenocarcinoma, but also in squamous cell carcinoma to allow accurate diagnosis and treatment.